Purification of essentially RNA free plasmid DNA using a modified Escherichia coli host strain expressing ribonuclease A

被引:21
作者
Cooke, GD
Cranenburgh, RM
Hanak, JAJ
Dunnill, P
Thatcher, DR
Ward, JM
机构
[1] UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England
[2] UCL, Dept Biochem Engn, Adv Ctr Biochem Engn, London WC1E 7JE, England
[3] Univ Keele, Cobra Therapeut Ltd, Keele ST5 5SP, Staffs, England
[4] Univ Oxford, Dept Biochem, Div Mol Genet, Oxford OX1 3QU, England
基金
英国生物技术与生命科学研究理事会;
关键词
chromosomal integration; periplasm; RNase; gene therapy;
D O I
10.1016/S0168-1656(00)00378-3
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Regulatory agencies have stringent requirements for the large-scale production of biotherapeutics. One of the difficulties associated with the manufacture of plasmid DNA for gene therapy is the removal of the host cell-related impurity RNA following cell lysis. We have constructed a modified Escherichia coli JM107 plasmid host (JMR-NaseA), containing a bovine pancreatic ribonuclease (RNaseA) expression cassette, integrated into the host chromosome at the dif locus. The expressed RNaseA is translocated to the periplasm of the cell, and is released during primary plasmid extraction by alkaline lysis. The RNaseA protein is stable throughout incubation at high pH (similar to 12-12.5), and subsequently acts to hydrolyse host cell RNA present in the neutralised solution following alkaline lysis. Results with this strain harbouring pUC18, and a 2.4 kb pUC18 Delta lacO, show that sufficient levels of ribonuclease (RNase) activity are produced to hydrolyse the bulk of the host RNA. This provides a suitable methodology for the removal of RNA, whilst avoiding the addition of exogenous animal sourced RNase and its associated regulatory requirements. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:297 / 304
页数:8
相关论文
共 26 条
  • [1] BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513
  • [2] IDENTIFICATION AND CHARACTERIZATION OF ASPARTATE RESIDUES THAT PLAY KEY ROLES IN THE ALLOSTERIC REGULATION OF A TRANSCRIPTION FACTOR - ASPARTATE-274 IS ESSENTIAL FOR INDUCER BINDING IN LAC REPRESSOR
    CHANG, WI
    BARRERA, P
    MATTHEWS, KS
    [J]. BIOCHEMISTRY, 1994, 33 (12) : 3607 - 3616
  • [3] Chen Z, 1998, Compositions and methods for rapid isolation of plasmid DNA, Patent No. [9816653, WO 98/16653]
  • [4] Monitoring impurities in biopharmaceuticals produced by recombinant technology
    DiPaolo, B
    Pennetti, A
    Nugent, L
    Venkat, K
    [J]. PHARMACEUTICAL SCIENCE & TECHNOLOGY TODAY, 1999, 2 (02): : 70 - 82
  • [5] *FDA, 1996, HUM GENE THER, V7, P1181
  • [6] Development of process flow sheets for the purification of supercoiled plasmids for gene therapy applications
    Ferreira, GNM
    Cabral, JMS
    Prazeres, DMF
    [J]. BIOTECHNOLOGY PROGRESS, 1999, 15 (04) : 725 - 731
  • [7] INVESTIGATION OF UNIT OPERATIONS INVOLVED IN CONTINUOUS-FLOW ISOLATION OF BETA-GALACTOSIDASE FROM ESCHERICHIA-COLI
    HIGGINS, JJ
    LEWIS, DJ
    DALY, WH
    MOSQUEIRA, FG
    DUNNILL, P
    LILLY, MD
    [J]. BIOTECHNOLOGY AND BIOENGINEERING, 1978, 20 (02) : 159 - 182
  • [8] HORN N, 1996, Patent No. 9621729
  • [9] CANCER GENE-THERAPY USING PLASMID DNA - PURIFICATION OF DNA FOR HUMAN CLINICAL-TRIALS
    HORN, NA
    MEEK, JA
    BUDAHAZI, G
    MARQUET, M
    [J]. HUMAN GENE THERAPY, 1995, 6 (05) : 565 - 573
  • [10] SITE-SPECIFIC RECOMBINATION IN THE REPLICATION TERMINUS REGION OF ESCHERICHIA-COLI - FUNCTIONAL REPLACEMENT OF DIF
    LESLIE, NR
    SHERRATT, DJ
    [J]. EMBO JOURNAL, 1995, 14 (07) : 1561 - 1570